-
-
-
-
-
-
-
Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit
-
-
-
-
-
-
-
Equillium (EQ) Reports Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study
-
-
-
-
-
-
-
Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates
-
-
-
-
-
-
-
Equillium (EQ) Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating. $12 PT on Equillium (EQ), Believes Phase 3 Study is "An Important Stepping Stone in Unlocking Pipeline Potential"
-
-
-
-
-
-
-
Pre-Open Stock Movers 03/31: (SURF) (CHWY) (CASI) Higher; (DCTH) (RMO) (CLSN) Lower (more...)
-
-
-
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

